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We report a case of severe fetal anemia associated with maternal anti-M
antibody that was treated by direct injection of pooled human
immunoglobulin into the fetal abdominal cavity. Four treatments at a
dosage of 2g per-kg estimated fetal body weight were performed, and no
side effects were observed. A healthy baby girl was delivered transvaginally at
38 weeks, with neither exchange transfusion nor phototherapy required.
Follow-up over 12 months found no indications of anemia or
developmental delay in the child. This is believed to be the ﬁrst report of
fetal anemia in a blood-type-incompatible pregnancy being treated
successfully with only direct immunoglobulin injection into the fetus. The
immunoglobulin may have functioned as a neutralizing antibody causing
the anemia to improve.
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Introduction
Trans-venous immunoglobulin injection (IVIG) to the mother and
fetal transfusion are the commonly used treatments for fetal
anemia in isoimmune hemolytic diseases of the fetus and
newborn (HDFN). IVIG to the mother is advocated as an
indirect fetal treatment option for neutralizing maternal red-cell
alloimmunization,
1 but several problems exist: the mother needs to
be injected with large amounts of immunoglobulin on a frequent
basis and the amount reaching the fetus cannot be measured,
veriﬁed or guaranteed. To the best of our knowledge, no previous
reports of cases in which fetal anti-anemic therapy with IVIG to the
mother was completed with neither fetal-blood transfusion nor
maternal-plasma exchange have been published. In this case,
severe fetal anemia associated with maternal anti-M antibody
2
was treated with immunoglobulin injected into the fetal
abdominal cavity (IFAC) without postnatal phototherapy or plasma
exchange.
Case
The mother was 22 years old (gravida 1; para 0) with no history
of transfusion; she consented to this study. Maternal blood type was
O/RhD positive and paternal blood type unknown.
Anti-M antibody was detected at 16-weeks gestation. Serological
investigations used polyethylene glycol-gel and enzyme-tube
methods. The antibody identiﬁcation was performed with a
commercially available panel (Ortho Clinical Diagnostics, Raritan,
NJ, USA). The indirect anti-globulin test (gel method) was
performed according to the manufacturer’s instructions. The direct
anti-globulin test (DAT) was performed after elution in gel cards
containing AHG (anti-human globulin) or anti-IgG, anti-IgM, or
anti-IgA and anti-C3b or anti-C3d, in separate wells. Both indirect
anti-globulin test and DAT were performed with commercially
available reagents (Ortho Clinical Diagnostics; Sysmex, Tokyo,
Japan). A summary of results for the tests on the mother and on
the fetus/infant is shown in Table 1.
The DAT was positive for IgG (Table 1). The mother was
conﬁrmed to be M antigen negative. Antibody titer was 1024 in the
indirect anti-globulin test, with subsequent tests performed every
4 weeks showing continued high antibody titer. Middle cerebral
artery peak systolic velocity was acutely elevated to 83.8cms
1
(1.6 MoM) at 30 weeks, and fetal anemia was conﬁrmed using
cordocentesis. The umbilical venous hemoglobin level was 6.4g per
100ml, the hematocrit level 17.9%, and the DAT results positive.
Immunoglobulin (Venoglobulin IH, Benesis, Tokyo, Japan) was
administered via direct immunoglobulin injection into the fetal
abdominal cavity (IFAC) at a dosage of 2g per-kg estimated fetal
body weight using a 25-gauge needle.
No side effects were observed during and after IFAC. After
1 week, the hemoglobin level increased to 7.3g per 100ml.
Three more IFAC treatments were carried out and ultrasonography
showed complete absorption of the injected immunoglobulin
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monitored and showed reassuringly steady improvement. Further,
IFAC treatment was therefore deemed unnecessary and
discontinued.
A baby girl weighing 2605g was delivered transvaginally at
38-weeks gestation. Apgar scores were 9/10 at 1/5min, respectively.
Following birth, the baby was screened and found to be M antigen
positive and DAT negative; her blood type was O/RhD positive. As
the mother was primigravida without a prior history of transfusion,
and the newborn infant tested positive for M antigen, it was
inferred that the HDFN was pregnancy induced. Infant hemoglobin
and hematocrit levels immediately after birth were 15.1g per
100ml and 41.2%, respectively; infant DAT results were positive on
day 0 and negative on day 6 (Table 1). On day 4, the hemoglobin
level was 16.1g per 100ml and hematocrit level was 41.2%, total
bilirubin was 17.5mg per 100mldl. Neither exchange transfusion
nor phototherapy was required. Mother and infant were discharged
on Day 6; follow-up over 16 months found no sequel or
developmental delay.
An unexpected phenomenon, the disappearance of maternal
anti-M antibodies (Table 1) during the course of the pregnancy
was observed. From this we speculated that IgGs from IFAC,
which may have transferred from the fetal to the maternal
circulation, may have had a role as in antibody
neutralization.
Discussion
We believe this to be the ﬁrst report of isoimmune HDFN being
treated successfully with IFAC (direct immunoglobulin injection
into the fetal abdominal cavity), without fetal blood transfusion,
postnatal phototherapy or plasma exchange.
Maternal anti-D immunoglobulin administration has been
established as a treatment to prevent isoimmunization in Rh-D
HDFN, but there are currently no clear treatment guidelines for
minor blood-group type incompatibility. Such pregnancies are
frequently managed in a similar manner to Rh-D incompatible
pregnancies,
1 and severe fetal hemolytic disease associated with
anti-M maternal immunization has been reported.
2 Fetal/neonatal
complications from anti-M antibodies are thought to be extremely
rare, even when the fetus is clearly M positive, and the great
majority of pregnant women found to have anti-M antibody do not
require cordocentesis or fetal IVIG administration. However, anti-M
antibodies can cause fetal hydrops as reported,
2 and the incidence
of MN incompatibilities in the Japanese population seems to be
higher than predicted.
3
Some proposed mechanisms by which IVIG may reduce HDFN
in fetuses and newborns are: (1) functions as a neutralizing
antibody; (2) prevents antibody-combined cell destruction by
blocking Fc receptors in the reticuloendothelial system; (3) aids
deposition of the immune complex; (4) increases suppressor
T-cells; and (5) decreases killer cells and peripheral
lymphocytes.
4–6
Reports indicate that in IVIG to the mother, the treatment is
expensive because the mother needs to be injected with large
amounts of immunoglobulin to neutralize all the alloimmune
antibodies within the maternal circulation.
4,6 Moreover, although
an amount of immunoglobulin administered via IVIG could exert
positive effects on the fetus, whether or not speciﬁc amounts of
immunoglobulin reach the fetus through the mother in IVIG
cannot yet be veriﬁed, measured or guaranteed. In IFAC, however,
the injection is targeted directly into the fetal abdominal cavity and
the amount of immunoglobulin injected is very low. Accordingly,
the procedure is inexpensive and the risk of side effects to the
mother is very low.
Immunoglobulin administration for pregnant women is
classiﬁed as ‘Category C’ (Risk cannot be ruled out) by the United
States Food and Drug Administration (FDA) (http://www.fda.gov).
Immunoglobulin intravenous (IGIV) products have been reported
to be associated with such side effects as renal dysfunction, acute
renal failure, osmotic nephrosis, acute hemolysis
7,8and death.
However, most of the adverse effects associated with IVIG are mild
and transient, and it is generally considered to be a safe therapy.
9
Although in IFAC some immunoglobulin may transfer from the
fetus into the maternal circulation through the placenta, the
amount is presumed to be far too low to exert any side effects on
the mother.
In the fetus, renal function is generally assessed by measuring
bladder and amniotic volume using ultrasound, or more precisely
measured using cordocentesis. In this case, the fetus had already
developed hydrops fetalis (severe cardiac failure due to severe
anemia), and we therefore assessed the fetal status using
cordocentesis (fetal creatinine, fetal blood urea nitrogen, fetal
bilirubin and so on.), cardiotocogram (CTG) and Doppler
ultrasound. Neither fetal renal dysfunction nor deterioration of
hemolysis was observed during the fetal therapy.
Although maternal IVIG is used in HDFN in addition to
maternal/infant-plasma exchange and/or fetal transfusion, no
favorable outcomes have been reported for IVIG used alone without
fetal transfusion.
10 IVIG can dilute pathogenic antibodies
transferring from the mother to the fetus, but the effect cannot be
guaranteed and the fetus continues sending alloimmune antigens
to the mother. In contrast, IFAC may function as a fundamental
defense against the attack of maternal alloimmune antibodies on
the fetal side.
Both intra-abdominal and percutaneous cordocentesis, fetal-
blood transfusion present technical risks and risks of infection.
Reports have been made of cordocentesis procedure-related
complication rates of up to 3.1%, resulting in an overall procedure-
related fetal loss rate of 1.6%.
11 However, IFAC presents less
technical risk and lower cost than fetal-blood transfusion.
12,13
The safety of immunoglobulin for the fetus is presumed for the
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ﬁltrated formula, and is therefore assumed to be safer than blood
transfusion with respect to infection; (2) use of immunoglobulin in
the treatment of HDFN has been established in pediatrics; and
(3) immunoglobulin is also used in the treatment of neonatal
hematological diseases related to the proposed mechanisms by
which IVIG may reduce HDFN in fetuses and newborns, including
immune platelet disorders (neonatal alloimmune
thrombocytopenia, postransfusion purpura and so on.); bleeding
disorders (acquired von Willebrand syndrome and so on.); and
other disorders such as parvovirus B19-infected red-cell aplasia.
14,15
IFAC can also prevent a direct burden on the cardiac system in a
fetus suffering hydrops fetalis, and has already been used to treat
fetal cytomegalovirus infection and parvovirus B19 infection.
12,13
In this case, the amount of immunoglobulin injected into the
fetus (2gkg
1), the maximum dosage, was calculated on the basis
of neonatal treatment of Kawasaki disease.
16 However, the actual
dosage that circulated in the fetus’s system is presumed to have
been lower than 2gkg
1, because in IFAC the immunoglobulin is
injected directly into the fetal abdominal cavity and not directly
into the fetal venous system. As fetal circulation comprises both the
fetus and the placenta, the dosage of injected immunoglobulin
could be diluted by the blood in the placenta and surplus
immunoglobulin could be absorbed by the maternal circulation
through the placenta. Thus, an ‘immunoglobulin overdose’ is
potentially impossible when IFAC is used.
Conclusion
In this case IFAC (immunoglobulin injection into the fetal
abdominal cavity) was successfully used alone, without postnatal
phototherapy or plasma exchange to treat fetal hydrops caused by
anemia because of pregnancy-induced anti-M antibodies causing
fetal hemolysis. Although more reported cases of IFAC therapy are
required to establish its efﬁcacy, this procedure seems to be a
promising treatment option for HDFN because of its safety, low cost
and effectiveness as a direct symptomatic treatment.
Conﬂict of interest
The authors declare no conﬂict of interest.
References
1 The American College of Obstetricians and Gynecologists Practice Bulletin No. 75
Management of alloimmunization. Obstet Gynecol 2006; 108: 457.
2 Wilkman A, Edner A, Gryfelt G, Jonsson B, Henter JI. Fetal hemolytic anemia
and intrauterine death caused by anti-M immunization. Transfusion 2007; 47(5):
911–917.
3 Serizawa M, Matsui H, Oishi A, Maeda T, Sudoko K, Ohashi T et al. A case of hydrops
fetalis caused by MN blood group incompatibility. Jpn J Obstetr Gynecol Neonatal
Hematol 1999; 8: 145–152.
4 NIH Consensus Conference. Intravenous Immunoglobulin: Prevention and Treatment
of Disease. J Am Med Assoc 1990; 264: 3189–3193.
Table 1 Follow-up of severe fetal anemia due to anti-M antibody
Mother Fetus
Weeks of
gestation
Titer of
anti-M
MCA-PSV
(MoM)
a
Hb
(g per100ml)
Ht
(%)
T-Bil
(mg per100ml)
Direct antiglobulin
test (DAT)
IFAC
(g)
b
Pregnancy 16 1024 FF F F F
F
27 1024 FF F F F
F
32 1024 >1.5 6.4 17.9 2.7 Positive
3.6
33 FF 7.3 21.9 2.2 Positive
4.0
34 128 >1.5 8.1 24.9 2.5 Positive
4.0
35 128 F 10.1 30.7 2.6 Positive
4.3
36 F 1.1 11.5 33.9 0.8 Positive
F
Delivery 38 FF 15.1 41.2 3.5 Positive
F
After delivery 6 days FF 14.8 41.3 15.0 Negative
aMultiples of the median peak systolic velocity in the middle cerebral artery.
bImmunoglobulin injected into the fetal abdominal cavity.
Immunoglobulin injection diminishes fetal anemia
H Matsuda et al
291
Journal of Perinatology5 Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inﬂammatory activity of immunoglobulin
G resulting from Fc sialylation. Science 2006; 313(5787): 670–673.
6 Nimmerjahn F, Ravetch JV. Anti-inﬂammatory activity of intravenous
immunoglobulin. Annu Rev Immunol 2008; 26: 513–533.
7 Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A et al. Acute hemolysis
after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
Clin J Am Soc Nephrol 2009; 4: 1993–1997.
8 Orbach H, Katz U, Sherer Y, Shoenﬁeld Y. Intravenous immunoglobulin: adverse effects
and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173–184.
9 Orange JS, Hossny EM, Weiler CR, Ballow M; Berger M, Bonilla FA et al. Use of
intravenous immunoglobulin in human disease: A review of evidence by members of
the Primary Immunodeﬁciency Committee of the American Academy of Allergy,
Asthma and Immunology. J Allergy Clin Immunol 2006; 117(4 Suppl): S525–S553.
10 Porter TF, Silver RM, Jackson GM, Branch DW, Scott JR. Intravenous immune globulin
in the management of severe Rh D hemolytic disease. Obstet and Gynecol Survey
1997; 52(3): 193–197.
11 Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vandenbussche FP
et al. Complications of intrauterine intravascular transfusion for fetal anemia
due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192(1):
171–177.
12 Matsuda H, Kawakami Y, Furuya K, Kikuchi Y. Intrauterine therapy for a
cytomegalovirus infected symptomatic fetus. BJOG 2004; 111(7): 756–757.
13 Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K.
Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich
high titer gammaglobulin. J Perinat Med 2005; 33: 561–563.
14 Aref K, Boctor FN, Pande S, Uehlinger J, Manning F, Eglowstein M et al. Successful
perinatal management of hydrops fetalis due to hemolytic disease associated with
Dmaternal phenotype. J Perinatology 2002; 22: 667–668.
15 Mundy CA. Intravenous immunoglobulin in the management of hemolytic disease of
the newborn. Neonatal Netw 2005; 24(6): 17–24.
16 Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous
gamma-globulin and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;
17: 1144.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
DerivativeWorks3.0UnportedLicense.Toviewacopyof
thislicense,visithttp://creativecommons.org/licenses/by-
nc-nd/3.0/
Immunoglobulin injection diminishes fetal anemia
H Matsuda et al
292
Journal of Perinatology